CDK/HDAC-IN-3

CDK/HDAC-IN-3

• CAS Number: 2944087-54-9
• UNSPSC Description: CDK/HDAC-IN-3 is an orally active HDACs/CDKs dual inhibitor. CDK/HDAC-IN-3 has potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2 and HDAC3 with IC50 values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28nM and 82.87 nM. CDK/HDAC-IN-3 can be used for the acute myeloid leukemia (AML) [1].
• Target Antigen: CDK; HDAC
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Epigenetics
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/cdk-hdac-in-3.html
• Solubility: DMSO : 125 mg/mL (ultrasonic)
• Smiles: NC1=C(C=CC=C1)NC(C2=CC=C(C=C2)NC(C3=NNC=C3NC(C4=C(C=CC=C4Cl)Cl)=O)=O)=O
• Molecular Weight: 509.34
• References & Citations: [1]Liu Y, et al. Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells. Eur J Med Chem. 2023;249:115140.
• Shipping Conditions: Blue Ice
• Clinical Information: No Development Reported